Skip to content

Total debt at other companies

Supernus Pharmaceuticals logo
Supernus PharmaceuticalsSUPN
$40.9M+26.6%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$7.49M-13.6%
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX
$1.4M+31.3%
Biohaven logo
BiohavenBHVN
$286.18M+706%
Septerna, Inc. logo
Septerna, Inc.SEPN
$23.09M-7.7%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY

Other financials

Income statement

See full
Revenue$20.0M
Operating income-$24.2M+10.7%
Net income-$19.9M+17.5%
EPS (diluted)-$0.42+38.2%

Balance sheet

See full
Cash & equivalents$78.1M+35.5%
Total equity$471.5M+65.0%
Total assets$497.6M+64.7%

Cash flow

See full
Operating cash flow-$13.1M+35.5%
CapEx$86.0K-70.4%
Free cash flow-$13.1M+36.0%

Valuation

See full
Market cap$1.86B+309%
Enterprise value$1.79B+352%

Returns & leverage

See full
Return on equity-28.3%
Debt / equity0.0×
Current ratio27.1×-3.9×

Where this comes from

Computed from long term debt + current portion long term debt + short term borrowings + operating lease liabilities + finance lease liabilities + financing obligations: $10.8M.

The official record: Rapport Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rapport Therapeutics, Inc.'s total debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rapport Therapeutics, Inc.'s total debt?
Rapport Therapeutics, Inc. (RAPP) reported total debt of $10.8M in Q1 2026.
How has Rapport Therapeutics, Inc.'s total debt changed year-over-year?
Rapport Therapeutics, Inc.'s total debt increased by 37.8% year-over-year, from $7.84M to $10.8M.
What is the long-term trend for Rapport Therapeutics, Inc.'s total debt?
Over 2 years (2023 to 2025), Rapport Therapeutics, Inc.'s total debt has grown at a 131.3% compound annual growth rate (CAGR), from $2.15M to $11.48M.
What does total debt mean?
Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.